474 — Aceso Life Science Cashflow Statement
0.000.00%
Last trade - 00:00- HK$841.55m
- HK$3.46bn
- HK$228.00m
Annual cashflow statement for Aceso Life Science, fiscal year end - March 31st, HKD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | ARS | ARS | ARS | ARS | |
| Standards: | HKAS | HKAS | HKAS | HKAS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | -267 | -323 | -555 | -213 | — |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 252 | 402 | 592 | 251 | — |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -398 | 37 | 211 | 132 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -356 | 179 | 316 | 222 | — |
| Capital Expenditures | -36.2 | -15 | -57 | -47 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 1,030 | 15 | -384 | -73 | — |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 994 | 0 | -441 | -120 | — |
| Financing Cash Flow Items | -214 | -113 | -163 | 43 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -522 | -375 | 126 | -98 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 115 | -184 | -3 | -8 | — |